Segment Reporting (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($) segment	Dec. 31, 2024 USD ($)
Segment Reporting [Abstract]
Number of operating segments | segment	1
Number of reportable segments | segment	1
Segment Reporting Information [Line Items]
Total revenue	$ 4,413	$ 4,055
Total research and development	39,750	32,126
General and administrative	27,579	26,686
Total operating expenses	67,329	58,812
Loss from operations	(62,916)	(54,757)
Other (expense) income :
Interest expense	922	1,251
Interest expense	(5,188)	(688)
Other (expense) income, net	(664)	140
Total other (expense) income	(4,930)	703
Net loss	(67,846)	(54,054)
Collaborative arrangement revenue
Segment Reporting Information [Line Items]
Total revenue	4,413	4,055
Total research and development	2,000	1,900
Reportable Segment
Segment Reporting Information [Line Items]
Research and development personnel costs	16,786	12,992
Facilities and other support costs	3,581	2,984
Other	2,581	2,294
Total research and development	39,750	32,126
General and administrative	27,579	26,686
Total operating expenses	67,329	58,812
Loss from operations	(62,916)	(54,757)
Other (expense) income :
Interest expense	922	1,251
Interest expense	(5,188)	(688)
Other (expense) income, net	(664)	140
Total other (expense) income	(4,930)	703
Net loss	(67,846)	(54,054)
Reportable Segment | OCU400
Segment Reporting Information [Line Items]
Research and development expense (excluding acquired in process cost)	9,871	6,846
Reportable Segment | OCU410 and OCU410ST
Segment Reporting Information [Line Items]
Research and development expense (excluding acquired in process cost)	5,465	3,653
Reportable Segment | NeoCart
Segment Reporting Information [Line Items]
Research and development expense (excluding acquired in process cost)	295	489
Reportable Segment | COVAXIN
Segment Reporting Information [Line Items]
Research and development expense (excluding acquired in process cost)	(2)	25
Reportable Segment | Inhaled mucosal vaccine platform
Segment Reporting Information [Line Items]
Research and development expense (excluding acquired in process cost)	417	2,464
Reportable Segment | OCU200
Segment Reporting Information [Line Items]
Research and development expense (excluding acquired in process cost)	756	379
Reportable Segment | Collaborative arrangement revenue
Segment Reporting Information [Line Items]
Total revenue	$ 4,413	$ 4,055